In 2024, the World Health Organization (WHO) reported that noncommunicable diseases (NCDs) account for approximately 75% of all deaths worldwide.
For pharmaceutical and biotech companies working in CVRMs, understanding future disease burden is essential to long-term strategy in order to inform decisions regarding where, when and how to invest resources for maximum impact of return. This is important when developing therapeutic interventions, but also for identifying where those interventions can have the greatest impact, and for making the case to act sooner.
In this context, epidemiological modelling is playing a growing role in evidence generation.
When you need a future-facing decision engine for big, real world population health questions, we are the people to turn to.
Solutions